SRZN Stock Overview
A biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Surrozen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.00 |
| 52 Week High | US$18.17 |
| 52 Week Low | US$6.00 |
| Beta | 0.69 |
| 1 Month Change | -22.35% |
| 3 Month Change | -19.57% |
| 1 Year Change | -7.69% |
| 3 Year Change | -80.33% |
| 5 Year Change | n/a |
| Change since IPO | -94.07% |
Recent News & Updates
Recent updates
Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky
Dec 04
Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation
Aug 21Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?
Jan 03Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?
Jun 19Here's Why Surrozen (NASDAQ:SRZN) Must Use Its Cash Wisely
Feb 12Surrozen stock rises ~13% premarket on licensing deal with Boehringer Ingelheim
Oct 06Surrozen GAAP EPS of -$0.40 beats by $0.06
Aug 11Surrozen CEO Craig Parker - Biotechs Can Never Be Too Well Capitalized (Video)
Oct 14Shareholder Returns
| SRZN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.2% | 1.3% | 5.8% |
| 1Y | -7.7% | -11.3% | 4.8% |
Return vs Industry: SRZN exceeded the US Biotechs industry which returned -11.9% over the past year.
Return vs Market: SRZN underperformed the US Market which returned 3.6% over the past year.
Price Volatility
| SRZN volatility | |
|---|---|
| SRZN Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: SRZN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SRZN's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 41 | Craig Parker | www.surrozen.com |
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, for treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases.
Surrozen, Inc. Fundamentals Summary
| SRZN fundamental statistics | |
|---|---|
| Market cap | US$76.45m |
| Earnings (TTM) | -US$63.56m |
| Revenue (TTM) | US$10.66m |
7.2x
P/S Ratio-1.2x
P/E RatioIs SRZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRZN income statement (TTM) | |
|---|---|
| Revenue | US$10.66m |
| Cost of Revenue | US$21.13m |
| Gross Profit | -US$10.48m |
| Other Expenses | US$53.09m |
| Earnings | -US$63.56m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.48 |
| Gross Margin | -98.33% |
| Net Profit Margin | -596.57% |
| Debt/Equity Ratio | 0% |
How did SRZN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 12:27 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Surrozen, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Yatin Suneja | Guggenheim Securities, LLC |
| Matthew Caufield | H.C. Wainwright & Co. |